264 related articles for article (PubMed ID: 2508608)
1. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1989 Oct; 46(10):1052-60. PubMed ID: 2508608
[TBL] [Abstract][Full Text] [Related]
2. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group.
Shoulson I
Acta Neurol Scand Suppl; 1989; 126():171-5. PubMed ID: 2515723
[TBL] [Abstract][Full Text] [Related]
3. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Shoulson I
Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
[TBL] [Abstract][Full Text] [Related]
4. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
[TBL] [Abstract][Full Text] [Related]
6. Effect of deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1989 Nov; 321(20):1364-71. PubMed ID: 2509910
[TBL] [Abstract][Full Text] [Related]
7. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
[TBL] [Abstract][Full Text] [Related]
8. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
[TBL] [Abstract][Full Text] [Related]
9. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.
Kieburtz K; McDermott M; Como P; Growdon J; Brady J; Carter J; Huber S; Kanigan B; Landow E; Rudolph A
Neurology; 1994 Sep; 44(9):1756-9. PubMed ID: 7936311
[TBL] [Abstract][Full Text] [Related]
10. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Shoulson I
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
[TBL] [Abstract][Full Text] [Related]
11. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1993 Jan; 328(3):176-83. PubMed ID: 8417384
[TBL] [Abstract][Full Text] [Related]
12. Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group.
LeWitt PA
Acta Neurol Scand Suppl; 1991; 136():79-86. PubMed ID: 1801542
[TBL] [Abstract][Full Text] [Related]
13. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
14. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
LeWitt PA
J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
[TBL] [Abstract][Full Text] [Related]
16. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
Marras C; Lang AE; Eberly SW; Oakes D; Fahn S; Schwid SR; Hyson C; Shoulson I;
Mov Disord; 2009 Dec; 24(16):2370-8. PubMed ID: 19908310
[TBL] [Abstract][Full Text] [Related]
17. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
Presthus J; Hajba A
Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
[TBL] [Abstract][Full Text] [Related]
18. Freezing of gait in PD: prospective assessment in the DATATOP cohort.
Giladi N; McDermott MP; Fahn S; Przedborski S; Jankovic J; Stern M; Tanner C;
Neurology; 2001 Jun; 56(12):1712-21. PubMed ID: 11425939
[TBL] [Abstract][Full Text] [Related]
19. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Tetrud JW; Langston JW
J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
[TBL] [Abstract][Full Text] [Related]
20. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group.
Shults CW
Acta Neurol Scand Suppl; 1993; 146():36-42. PubMed ID: 8333252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
